| | 475108-18-0 Basic information More.. |
| Product Name: | Tivozanib | | Synonyms: | AV-951;Tivozanib;N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea;AV-951(Tivozanib);1-(2-Chloro-4-(6,7-diMethoxyquinolin-4-yloxy)phenyl)-3-(5-Methylisoxazol-3-yl)urea;TIVOZANIB;AV951;KRN951, TIVOZANIB) (STOPPED USE SINCE THE PATENT ISSUE;N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)aMino]benzaMide | | CAS: | 475108-18-0 | | MF: | C22H19ClN4O5 | | MW: | 454.86 | | EINECS: | | | Mol File: | 475108-18-0.mol |  |
Use
Tivozanib is known as an oral VEGF receptor tyrosine kinase inhibitor, exhibiting antitumor effects towards renal cell carcinoma.. Tivozanib suppresses angiogenesis by selectively inhibiting against v
ascular endothelial growth factor.
- Tivozanib
-
- $34.00
- 2026-06-02
- CAS:475108-18-0
- Purity: 99.67%
- Supply Ability: 10g
- Tivozanib
-
- 2026-03-27
- CAS:475108-18-0
- Min. Order: 1g
- Purity: 98% HPLC
- Supply Ability: 1kg
|
|
475108-18-0
Recommend Suppliers |
|